AUTHOR INDEX

AARONS, L. *see* SIMPSON, J.A.
ABBOTT, R. *see* SIDHU, J.
ACUÑA, M., EATON, L., CIFUENTES, L. & MASSARDO, D. Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population: 778
AITIO, M.-L. N-acetylcysteine – passe-partout or much ado about nothing?: 5
ALAM, C.A.S. *see* CHIK, Z.
ALAM, C.A.S. Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males: 275ALFARO, R.M. *see* ROBERTSON, S.M.
ALLAIN, T.J. *see* DHESI, J.K.
ALLEGAERT, K., ANDERSON, B.J., COSSEY, V. & HOLFORD, N.H.G. Limited predictability of amikacin clearance in extreme premature neonates at birth: 39
ALVES, V.M.N. *see* SIMOES, J.A.
ANDERSON, B.J. *see* ALLEGAERT, K.
ANTIKAINEN, M. *see* HEDMAN, M.
ARONSON, J.K. A prescription for better prescribing: 487
ARONSON, J.K. Clinical Pharmacology: Past, Present, and Future: 647
ARONSON, J.K. Medicines and the media: 121
ARONSON, J.K. Monitoring for harms of therapy: 365
ARONSON, J.K. Rare diseases and orphan drugs: 243
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BABER, N.S., BEGG, E.J. & LEWIS, L.D. Today's science, tomorrow's medicines: 1
ARONSON, J.K., LENNARD, M.S., RITTER, J.M., BABER, N.S., BEGG, E.J. & LEWIS, L.D. Editors' Report 2005: 492
ASCHER, J. *see* SIDHU, J.
AUDIKOVSZKY, M. *see* PARAGH, G.
AVERY, A. *see* CLAYTON, J.A.

BABER, N.S. *see* ARONSON, J.K.
BACKMAN, J.T. *see* JAAKKOLA, T.
BAHAMONDES, L.G. *see* SIMOES, J.A.
BAILEY, D.G. *see* TIRONA, R.G.
BARROW, P., WALLER, P. & WISE, L. Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions: 233
BEARD, K. *see* WALLER, P.C.
BECK, C.R. *see* REHILL, N.
BEDDING, A.W. *see* FORGUE, S.T.
BEGG, E.J. *see* ARONSON, J.K.
BEGG, E.J. *see* GARDINER, S.J.
BEGGS, S. *see* TITCHEN, T.
BENKO, R. *see* MATUZ, M.
BERGSTRAND, I.C. *see* MAGNUSSON, M.
BERNSDORF, A., GIESSMANN, T., MODESS, C., WEGNER, D., IGELBRINK, S., HECKER, U., HAENISCH, S., CASCORBI, I., TERHAAG, B. & SIEGMUND, W. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms: 440
BERTELE, V. *see* JOPPI, R.
BERTRAND, X. *see* MULLER, A.
BEYER, J. & SCHELLONG, S. Bilateral plantar tendinitis during levofloxacin therapy: 609
BIAGINI, G.A. *see* EDWARDS, G.
BIDSTRUP, T.B., DAMKIER, P., OLSEN, A.K., EKBLOM, M., KARLSSON, A. & BRØSEN, K. The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide: 49
BIERMASZ, N.R. *see* PEREIRA, A.M.
BIES, R.R. *see* FENG, Y.
BINH, V.Q. *see* CUONG, B.T.
BJÖRKMAN, S. *see* MAGNUSSON, M.
BLAKEY, J. *see* CLAYTON, J.A.
BLOM, A.T.G. *see* HUGTENBURG, J.G.
BOJANG, K. *see* SIMPSON, J.A.
BOYD, I.W., MCEWEN, J. & CALCINO, L.J. A study of codispensing with sodium alendronate in Australia: 470
BOZZELLA, R. *see* BRUNNER, M.
BRØSEN, K. *see* BIDSTRUP, T.B.
BRADSHAW, C.M. *see* HOU, R.H.
BRAMSON, C. *see* OUELLET, D.
BRANCO, T. *see* PEREIRA, S.A.
BRUNNER, M., ZIEGLER, S., DI STEFANO, A.F.D., DEHGHANYAR, P., KLETTER, K., TSCHURLOVITS, M., VILLA, R., BOZZELLA, R., CELASCO, G., MORO, L., RUSCA, A., DUDCZAK, R. & MÜLLER, M. Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation: 31
BUDINSKY, A. *see* RESCH, U.
BULLMAN, J. *see* SIDHU, J.
BURGER, D., VAN DER HEIDEN, I., LA PORTE, C., VAN DER ENDE, M., GROENEVELD, P., RICHTER, C., KOOPMANS, P., KROON, F., SPRENGER, H., LINDEMANS, J., SCHENK, P. & VAN SCHAIK, R. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and *CYP2B6* polymorphism: 148
BURKEY, J.L. *see* YEO, K.P.
BYRNE, C. *see* STAATZ, C.E.

CAIXAS, U. *see* PEREIRA, S.A.
CALCINO, L.J. *see* BOYD, I.W.
CALLAHAN, M.M. *see* SIMOES, J.A.
CAMARGO, R.P.S. *see* SIMOES, J.A.
CAPRON, L. *see* WYPLOSZ, B.
CARDAROPOLI, S. *see* TODROS, T.
CARDOT, J.M. *see* CHASSAING, C.
CARVAJAL-GONZALEZ, S. *see* OUELLET, D.
CASCORBI, I. *see* BERNSDORF, A.
CASTEL, J.-M., FIGUERAS, A. & VIGO, J.-M. The internet as a tool in clinical pharmacology: 787
CELASCO, G. *see* BRUNNER, M.
CHASSAING, C., SCHMIDT, J., ESCHALIER, A., CARDOT, J.M. & DUBRAY, C. Hyperalgesia induced by cutaneous freeze injury for testing analgesics in healthy volunteers: 389
CHEW, S.L. *see* CHIK, Z.
CHIK, Z., JOHNSTON, A., TUCKER, A.T., CHEW, S.L., MICHAELS, L. & 'CHRIS' DELANEY, J.A., OPATRNY, L. & SUISSA, S. Warfarin use and the risk of motor vehicle crash in older drivers: 229
CHINITZ, D.P. *see* KAHAN, N.R.
CHOW, M.S.S. *see* TOMLINSON, B.
CIFUENTES, L. *see* ACUÑA, M.
CLARK, D.W.J. *see* HARRISON-WOOLRYCH, M.
CLAYTON, J.A., RODGERS, S., BLAKEY, J., AVERY, A. & HALL, I.P. Thiazide diuretic prescription and electrolyte abnormalities in primary care: 87
CÔRTE-REAL, R.M. *see* PEREIRA, S.A.
COLEMAN, J.J., FERNER, R.E. & EVANS, S.J.W. Monitoring for adverse drug reactions: 371
COLLER, J.K. *see* DAVIES, B.J.
COMINACINI, L. *see* MINUZ, P.
COMPAGNON, P. *see* JOANNIDES, R.
COSSEY, V. *see* ALLEGAERT, K.
CRANSWICK, N. *see* TITCHEN, T.
CUONG, B.T., BINH, V.Q., DUY, B.D.D.N., LOVELL, C.M., RIECKMANN, K.H. & EDSTEIN, M.D. Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?: 682

© 2006 Blackwell Publishing Ltd

DAIMON, T. *see* YAMADA, H.
DALLOW, N. *see* SINGH, D.
DAMKIER, P. *see* BIDSTRUP, T.B.
DAVIES, B.J., COLLER, J.K., JAMES, H.M., SOMOGYI, A.A., HOROWITZ, J.D. & SALLUSTIO, B.C. The influence of *CYP2D6* genotype on trough plasma perhexiline and *cis*-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia: 321
DE BOER, A. *see* MANTEL-TEEUWISSE, A.K.
DE BRUIJN, M. *see* HESSE, C.
DE HAAN, M. *see* VOLLEBREGT, J.A.
DE VRIES, M. *see* HESSE, C.
DE VRIES, T.P.G.M. *see* VOLLEBREGT, J.A.
DEBRECZENI, L. *see* PARAGH, G.
DEHGHANYAR, P. *see* BRUNNER, M.
DHESI, J.K., ALLAIN, T.J., MANGONI, A.A. & JACKSON, S.H.D. The implications of a growing evidence base for drug use in elderly patients. Part 4. Vitamin D and bisphosphonates for fractures and osteoporosis: 521
DI STEFANO, A.F.D. *see* BRUNNER, M.
DIELEMAN, J.P. *see* ZIERE, G.
DINGEMANSE, J., GUNAWARDENA, K.A. & VAN GIERSBERGEN, P.L.M. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects: 405
DOLLERY, C.T. Clinical pharmacology – the first 75 years and a view of the future: 650
DONNELLY, R., WANG, B. & QU, X. Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments: 702
DOOGUE, M.P. *see* GARDINER, S.J.
DORO, P. *see* MATUZ, M.
DUBRAY, C. *see* CHASSAING, C.
DUDCZAK, R. *see* BRUNNER, M.
DUFFULL, S.B. *see* FRIBERG, L.E.
DUY, B.D.D.N. *see* CUONG, B.T.

EATON, L. *see* ACUÑA, M.
EDSTEIN, M.D. *see* CUONG, B.T.
EDWARDS, G. & BIAGINI, G.A. Resisting resistance: dealing with the irrepressible problem of malaria: 690
EDWARDS, G. *see* SIMPSON, J.A.
EICHELBAUM, M. *see* HEDMAN, M.
EKBLOM, M. *see* BIDSTRUP, T.B.
ELLIOT, D.J. *see* POLASEK, T.M.
ELLIOT, D.J. *see* UCHAIPICHAT, V.
ENCK, P. *see* OTTO, B.
ERDEI, A. *see* PARAGH, G.
ESCHALIER, A. *see* CHASSAING, C.
EVANS, S.J.W. *see* COLEMAN, J.J.
EVANS, S.J.W. *see* WALLER, P.C.
EVERITT, S. *see* HAWKEY, C.J.

FAIFERMAN, I. *see* SINGH, D.
FALLOON, J. *see* ROBERTSON, S.M.
FAVA, C. *see* MINUZ, P.
FENG, Y., POLLOCK, B.G., FERRELL, R.E., KIMAK, M.A., REYNOLDS III, C.F. & BIES, R.R. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling: 558
FERNER, R.E. *see* COLEMAN, J.J.
FERRELL, R.E. *see* FENG, Y.
FERRO, A. *see* SAHA, M.
FIGUERAS, A. *see* CASTEL, J.-M.
FITZGERALD, C. *see* KIM, J.
FITZGERALD, D. *see* QUINN, M.
FORGUE, S.T., PATTERSON, B.E., BEDDING, A.W., PAYNE, C.D., PHILLIPS, D.L., WRISHKO, R.E. & MITCHELL, M.I. Tadalafil pharmacokinetics in healthy subjects: 280
FORMENTINI, E. *see* ROBERTSON, S.M.
FOSTER, D.J.R. *see* MORRISH, G.A.
FRANCIS, E. *see* SIDHU, J.
FREEMAN, C. *see* HOU, R.H.
FRIBERG, L.E., ISBISTER, G.K. & DUFFULL, S.B. Pharmacokinetic–pharmacodynamic modelling of QT interval prolongation following citalopram overdoses: 177
FURUTA, T., SHIRAI, N., SUGIMOTO, M., NAKAMURA, A. & HISHIDA, A. Hydroxylation of lansoprazole in poor metabolizers of CYP2C19: 361

GARATTINI, S. *see* JOPPI, R.
GARDINER, S.J., DOOGUE, M.P., ZHANG, M. & BEGG, E.J. Quantification of infant exposure to celecoxib through breast milk: 101
GARDNER, M.J. *see* OUELLET, D.
GARNER, R.C. & LAPPIN, G. The phase 0 microdosing concept: 367
GERMANO, I. *see* PEREIRA, S.A.
GIESSMANN, T. *see* BERNSDORF, A.
GILLAM, E.M.J. *see* POLASEK, T.M.
GOLDMAN, M. *see* SINGH, D.
GOOSEN, A. *see* SINGH, D.
GOTO, F. *see* TAKIZAWA, E.
GRAY, D. *see* HAWKEY, C.J.
GRIMM, S.W., RICHTAND, N.M., WINTER, H.R., STAMS, K.R. & REELE, S.B. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics: 58
GROENEVELD, P. *see* BURGER, D.
GROVER, A. *see* SIDHU, S.
GRUNAU, R.E. *see* KIM, J.
GUNAWARDENA, K.A. *see* DINGEMANSE, J.
GUNNELL, D. *see* MARTIN, R.M.

HAEFELI, W.E. *see* HESSE, C.
HAENISCH, S. *see* BERNSDORF, A.
HAJDU, E. *see* MATUZ, M.
HALL, I.P. *see* CLAYTON, J.A.
HARANGI, M. *see* PARAGH, G.
HARRISON-WOOLRYCH, M., CLARK, D.W.J., HILL, G.R., REES, M.I. & SKINNER, J.R. QT interval prolongation associated with sibutramine treatment: 464
HAUBEN, M. & REICH, L. Response to letter by Levine *et al*: 115
HAWKEY, C.J., HAWKEY, G.M., EVERITT, S., SKELLY, M.M., STACK, W.A. & GRAY, D. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs: 730
HAWKEY, G.M. *see* HAWKEY, C.J.
HÉNON, T. *see* MULLER, A.
HECKER, U. *see* BERNSDORF, A.
HEDMAN, M., ANTIKAINEN, M., HOLMBERG, C., NEUVONEN, M., EICHELBAUM, M., KIVISTÖ, K.T., NEUVONEN, P.J. & NIEMI, M. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the *SLCO1B1* and *ABCB1* genes: 706
HEIJL, A. *see* MAGNUSSON, M.
HENDERSON, A. *see* SINGH, D.
HESSE, C., LUNTZ, S.P., SIEDLER, H., UNNEBRINK, K., MIKUS, G., DE BRUIJN, M., ZONDAG, E., DE VRIES, M., SEIBERT-GRAFE, M. & HAEFELI, W.E. Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals: 414
HILL, G.R. *see* HARRISON-WOOLRYCH, M.
HIRAOKA, H. *see* TAKIZAWA, E.
HISHIDA, A. *see* FURUTA, T.
HÖGLUND, P. *see* MAGNUSSON, M.
HO, W.F. *see* KOO, S.H.
HOFMAN, A. *see* MANTEL-TEEUWISSE, A.K.
HOFMAN, A. *see* ZIERE, G.
HOLFORD, N.H.G. *see* ALLEGAERT, K.
HOLMBERG, C. *see* HEDMAN, M.
HOROWITZ, J.D. *see* DAVIES, B.J.
HOSSEINI, S.Y. *see* SAFARINEJAD, M.R.
HOU, R.H., SCAIFE, J., FREEMAN, C., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine: 752
HSU, E. Reflections on the 'discovery' of the antimalarial *qinghao*: 666
HUGHES, D. *see* SIMPSON, J.A.
HUGTENBURG, J.G. *see* VOLLEBREGT, J.A.

HUGTENBURG, J.G., BLOM, A.T.G. & KISOENSINGH, S.U. Initial phase of chronic medication use; patients' reasons for discontinuation: 352

IACOB, M. *see* JOANNIDES, R.
IGELBRINK, S. *see* BERNSDORF, A.
ILLYÉS, L. *see* PARAGH, G.
ISBISTER, G.K. *see* FRIBERG, L.E.
ISHII, K. *see* TASHIRO, M.
ISHIWATA, K. *see* TASHIRO, M.

JAAKKOLA, T., BACKMAN, J.T., NEUVONEN, M., LAITILA, J. & NEUVONEN, P.J. Effect of rifampicin on the pharmacokinetics of pioglitazone: 70
JACKSON, S.H.D. *see* DHESI, J.K.
JACKSON, S.H.D. *see* MANGONI, A.A.
JAMES, H.M. *see* DAVIES, B.J.
JOANNIDES, R., MOORE, N., IACOB, M., COMPAGNON, P., LEREBOURS, G., MENARD, J.-F. & THUILLEZ, C. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise: 127
JOB, S. *see* SIDHU, J.
JOHNSTON, A. *see* CHIK, Z.
JOPPI, R., BERTELE, V. & GARATTINI, S. Orphan drug development is progressing too slowly: 355

KAGAYA, H. *see* MIURA, M.
KAHAN, E. *see* KAHAN, N.R.
KAHAN, N.R., CHINITZ, D.P., WAITMAN, D.-A. & KAHAN, E. When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians: 341
KAMALI, F. & PIRMOHAMED, M. The future prospects of pharmacogenetics in oral anticoagulation therapy: 746
KANABAR, D. Adverse drug reactions to NSAIDs: 240
KANEKO, S. *see* YASUI-FURUKORI, N.
KARLSSON, A. *see* BIDSTRUP, T.B.
KENT, N. *see* KIM, J.
KIM, J., RIGGS, K.W., MISRI, S., KENT, N., OBERLANDER, T.F., GRUNAU, R.E., FITZGERALD, C. & RURAK, D.W. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding: 155
KIMAK, M.A. *see* FENG, Y.
KIMURA, Y. *see* TASHIRO, M.
KISOENSINGH, S.U. *see* HUGTENBURG, J.G.
KIVISTÖ, K.T. *see* HEDMAN, M.
KLETTER, K. *see* BRUNNER, M.
KLOSE, J. *see* OTTO, B.
KLOSTERHALFEN, S. *see* OTTO, B.
KLUNGEL, O.H. *see* MANTEL-TEEUWISSE, A.K.
KNIGHTS, K.M., MANGONI, A.A. & MINERS, J.O. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?: 738
KOO, S.H., HO, W.F. & LEE, E.J.D. Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore: 301
KOOPMANS, P. *see* BURGER, D.
KOPPESCHAAR, H.P.F. *see* PEREIRA, A.M.
KOVÁCSAY, A. *see* PARAGH, G.
KROON, F. *see* BURGER, D.

LA PORTE, C. *see* BURGER, D.
LAITILA, J. *see* JAAKKOLA, T.
LAMPREIA, F. *see* PEREIRA, S.A.
LANGLEY, R.W. *see* HOU, R.H.
LAPPIN, G. *see* GARNER, R.C.
LASENBY, S. *see* SINGH, D.
LEE, E.J.D. *see* KOO, S.H.
LENNARD, M.S. *see* ARONSON, J.K.
LEREBOURS, G. *see* JOANNIDES, R.
LEVINE, J.G., TONNING, J.M. & SZARFMAN, A. Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned: 105
LEWINGTON, G. & MARSHALL, K. Access to emergency hormonal contraception from community pharmacies and family planning clinics: 605
LEWIS, B.C. *see* POLASEK, T.M.
LEWIS, L.D. *see* ARONSON, J.K.
LILLO-LE LOUËT, A. *see* WYPLOSZ, B.
LIM, M.T. *see* YEO, K.P.
LINDEMANS, J. *see* BURGER, D.
LOVELL, C.M. *see* CUONG, B.T.
LOWE, S.L. *see* YEO, K.P.
LUNTZ, S.P. *see* HESSE, C.

MACKENZIE, P.I. *see* UCHAIPICHAT, V.
MAGNUSSON, M., BERGSTRAND, I.C., BJÖRKMAN, S., HEIJL, A., ROTH, B. & HÖGLUND, P. A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans: 138
MAHMOOD, I. Prediction of drug clearance in children from adults: a comparison of several allometric methods: 545
MALHOTRA, S. *see* SIDHU, S.
MANGONI, A.A. & JACKSON, S.H.D. The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention: 494
MANGONI, A.A. & JACKSON, S.H.D. The implications of a growing evidence base for drug use in elderly patients. Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients: 502
MANGONI, A.A. & JACKSON, S.H.D. The implications of a growing evidence base for drug use in elderly patients. Part 3. β-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction: 513
MANGONI, A.A. *see* DHESI, J.K.
MANGONI, A.A. *see* KNIGHTS, K.M.
MANTEL-TEEUWISSE, A.K., KLUNGEL, O.H., HOFMAN, A., VERSCHUREN, W.M.M., TRIENEKENS, P.H., PORSIUS, A.J., STRICKER, B.H.CH. & DE BOER, A. Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992–1999): 592
MANYANDO, C. *see* SIMPSON, J.A.
MARSHALL, K. *see* LEWINGTON, G.
MARTIN, R.M., MAY, M. & GUNNELL,D. Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004: 224
MASSARDO, D. *see* ACUÑA, M.
MATUZ, M., BENKO, R., DORO, P., HAJDU, E., NAGY, G., NAGY, E., MONNET, D.L. & SOOS, G. Regional variations in community consumption of antibiotics in Hungary, 1996–2003: 96
MAUCK, C.K. *see* SIMOES, J.A.
MAY, M. *see* MARTIN, R.M.
MCEWEN, J. *see* BOYD, I.W.
MECHOULAM, R. Cannabinoids as Therapeutics: 242
MENARD, J.-F. *see* JOANNIDES, R.
METZ, J.C.M. *see* VOLLEBREGT, J.A.
MICHAELS, L. *see* CHIK, Z.
MIKUS, G. *see* HESSE, C.
MINERS, J.O. *see* KNIGHTS, K.M.
MINERS, J.O. *see* POLASEK, T.M.
MINERS, J.O. *see* UCHAIPICHAT, V.
MINUZ, P., FAVA, C. & COMINACINI, L. Oxidative stress, antioxidants, and vascular damage: 774
MISRI, S. *see* KIM, J.
MITCHELL, M.I. *see* FORGUE, S.T.
MIURA, M., KAGAYA, H., TADA, H., UNO, T., YASUI-FURUKORI, N., TATEISHI, T. & SUZUKI, T. Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes: 315
MOCHIZUKI, H. *see* TASHIRO, M.
MODESS, C. *see* BERNSDORF, A.
MONNET, D.L. *see* MATUZ, M.
MONNET, D.L. *see* MULLER, A.
MONTEIRO, E.C. *see* PEREIRA, S.A.

MOORE, N. *see* JOANNIDES, R.
MORO, L. *see* BRUNNER, M.
MORRISH, G.A., FOSTER, D.J.R. & SOMOGYI, A.A. Differential *in vitro* inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids: 326
MOTOMURA, S. *see* UNO, T.
MÜLLER, M. *see* BRUNNER, M.
MULLER, A., MONNET, D.L., TALON, D., HÉNON, T. & BERTRAND, X. Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital: 585
MURAKAMI, H. *see* MURAKAMI, Y.
MURAKAMI, Y., TANAKA, T., MURAKAMI, H., TSUJIMOTO, M., OHTANI, H. & SAWADA, Y. Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A: 671

NAGY, E. *see* MATUZ, M.
NAGY, G. *see* MATUZ, M.
NAKAMURA, A. *see* FURUTA, T.
NAKASHIMA, M. *see* YAMADA, H.
NATARAJAN, V. *see* ROBERTSON, S.M.
NEUVONEN, M. *see* HEDMAN, M.
NEUVONEN, M. *see* JAAKKOLA, T.
NEUVONEN, P.J. *see* HEDMAN, M.
NEUVONEN, P.J. *see* JAAKKOLA, T.
NIEMI, M. *see* HEDMAN, M.

O'SHAUGHNESSY, K.M. HapMap, pharmacogenomics, and the goal of personalized prescribing: 783
OBERLANDER, T.F. *see* KIM, J.
ODA, K. *see* TASHIRO, M.
OGGÈ, G. *see* TODROS, T.
OHKUBO, T. *see* UNO, T.
OHTANI, H. *see* MURAKAMI, Y.
OLSEN, A.K. *see* BIDSTRUP, T.B.
OPATRNY, L. *see* 'CHRIS' DELANEY, J.A.
OTTO, B., RIEPL, R.L., OTTO, C., KLOSE, J., ENCK, P. & KLOSTERHALFEN, S. μ-Opiate receptor agonists – a new pharmacological approach to prevent motion sickness?: 27
OTTO, C. *see* OTTO, B.
OUELLET, D., BRAMSON, C., CARVAJAL-GONZALEZ, S., ROMAN, D., RANDINITIS, E., REMMERS, A. & GARDNER, M.J. Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin: 741

PADOS, G. *see* PARAGH, G.
PALADINI, D. *see* TODROS, T.
PANDHI, P. *see* SIDHU, S.
PARAGH, G., SERES, I., HARANGI, M., ERDEI, A., AUDIKOVSZKY, M., DEBRECZENI, L., KOVÁCSAY, A., ILLYÉS, L. & PADOS, G. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome: 694
PATTERSON, B.E. *see* FORGUE, S.T.
PAYNE, C.D. *see* FORGUE, S.T.
PENZAK, S.R. *see* ROBERTSON, S.M.
PEREIRA, A.M., VAN DER KLAAUW, A.A., KOPPESCHAAR, H.P.F., SMIT, J.W.A., VAN THIEL, S.W., VAN DOORN, J., BIERMASZ, N.R., ROELFSEMA, F. & ROMIJN, J.A. Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency: 451
PEREIRA, S.A., BRANCO, T., CÔRTE-REAL, R.M., GERMANO, I., LAMPREIA, F., CAIXAS, U. & MONTEIRO, E.C. Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients: 601
PERUCCA, E. Clinically relevant drug interactions with antiepileptic drugs: 246
PHILIPSON, R. *see* SIDHU, J.
PHILLIPS, D.L. *see* FORGUE, S.T.
PIRMOHAMED, M. *see* KAMALI, F.
PISCITELLI, S.C. & RODVALD, K.A. Drug Interactions in Infectious Diseases, 2nd edn: 611
POLASEK, T.M., ELLIOT, D.J., SOMOGYI, A.A., GILLAM, E.M.J., LEWIS, B.C. & MINERS, J.O. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid: 570
POLLOCK, B.G. *see* FENG, Y.
POLS, H.A.P. *see* ZIERE, G.
PORSIUS, A.J. *see* MANTEL-TEEUWISSE, A.K.

QU, X. *see* DONNELLY, R.
QUINN, M. & FITZGERALD, D. Platelet function: assessment, diagnosis and treatment: 610

RAMAEKERS, J.G. *see* THEUNISSEN, E.L.
RANDINITIS, E. *see* OUELLET, D.
REELE, S.B. *see* GRIMM, S.W.
REES, M.I. *see* HARRISON-WOOLRYCH, M.
REHILL, N., BECK, C.R., YEO, K.R. & YEO, W.W. The effect of chronic tobacco smoking on arterial stiffness: 767
REICH, L. *see* HAUBEN, M.
REMMERS, A. *see* OUELLET, D.
RESCH, U., TATZBER, F., BUDINSKY, A. & SINZINGER, H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy: 262
REYNOLDS III, C.F. *see* FENG, Y.
RICHIR, M.C. *see* VOLLEBREGT, J.A.
RICHTAND, N.M. *see* GRIMM, S.W.
RICHTER, C. *see* BURGER, D.
RIECKMANN, K.H. *see* CUONG, B.T.
RIEPL, R.L. *see* OTTO, B.
RIGGS, K.W. *see* KIM, J.
RITTER, J. & WARREN, J. ASCOT – old or new drugs for blood pressure?: 363
RITTER, J.M. *see* ARONSON, J.K.
ROBERTSON, S.M., FORMENTINI, E., ALFARO, R.M., NATARAJAN, V., FALLOON, J. & PENZAK, S.R. Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort: 379
RODGERS, S. *see* CLAYTON, J.A.
RODVALD, K.A. *see* PISCITELLI, S.C.
ROELFSEMA, F. *see* PEREIRA, A.M.
ROMAN, D. *see* OUELLET, D.
ROMIJN, J.A. *see* PEREIRA, A.M.
ROTH, B. *see* MAGNUSSON, M.
RURAK, D.W. *see* KIM, J.
RUSCA, A. *see* BRUNNER, M.

SAFARINEJAD, M.R. & HOSSEINI, S.Y. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study: 456
SAHA, M. & FERRO, A. Cardiac stem cell therapy: present and future: 727
SAITO, S. *see* TAKIZAWA, E.
SAKURADA, Y. *see* TASHIRO, M.
SALLUSTIO, B.C. *see* DAVIES, B.J.
SASAKI, T. *see* TASHIRO, M.
SAWADA, Y. *see* MURAKAMI, Y.
SCAIFE, J. *see* HOU, R.H.
SCHELLONG, S. *see* BEYER, J.
SCHENK, P. *see* BURGER, D.
SCHMIDT, J. *see* CHASSAING, C.
SCHWARTZ, J. *see* SIMOES, J.A.
SEIBERT-GRAFE, M. *see* HESSE, C.
SERES, I. *see* PARAGH, G.
SESOKO, S. *see* YAMADA, H.
SHAFIQ, N. *see* SIDHU, S.
SHIMIZU, M. *see* UNO, T.
SHIMIZU, M., UNO, T., SUGAWARA, K. & TATEISHI, T. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein: 538
SHIRAI, N. *see* FURUTA, T.
SIDHU, J., JOB, S., BULLMAN, J., FRANCIS, E., ABBOTT, R., ASCHER, J. & THEIS, J.G.W. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects: 420
SIDHU, J., JOB, S., SINGH, S. &

PHILIPSON, R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects: 191
SIDHU, S., SHAFIQ, N., MALHOTRA, S., PANDHI, P. & GROVER, A. A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease: 720
SIEDLER, H. *see* HESSE, C.
SIEGMUND, W. *see* BERNSDORF, A.
SIMOES, J.A., BAHAMONDES, L.G., CAMARGO, R.P.S., ALVES, V.M.N , ZANEVELD, L.J.D., WALLER, D.P., SCHWARTZ, J., CALLAHAN, M.M. & MAUCK, C.K. A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis: 211
SIMPSON, J.A., HUGHES, D., MANYANDO, C., BOJANG, K., AARONS, L., WINSTANLEY, P., EDWARDS, G., WATKINS, W.A. & WARD, S. Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone: 289
SINGH, D., TAL-SINGER, R., FAIFERMAN, I., LASENBY, S., HENDERSON, A., WESSELS, D., GOOSEN, A., DALLOW, N., VESSEY, R. & GOLDMAN, M. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects: 398
SINGH, S. *see* SIDHU, J.
SINZINGER, H. *see* RESCH, U.
SKELLY, M.M. *see* HAWKEY, C.J.
SKINNER, J.R. *see* HARRISON-WOOLRYCH, M.
SMIT, J.W.A. *see* PEREIRA, A.M.
SOMOGYI, A.A. *see* DAVIES, B.J.
SOMOGYI, A.A. *see* MORRISH, G.A.
SOMOGYI, A.A. *see* POLASEK, T.M.
SOOS, G. *see* MATUZ, M.
SPRENGER, H. *see* BURGER, D.
STAATZ, C.E., BYRNE, C. & THOMSON, A.H. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery: 164
STACK, W.A. *see* HAWKEY, C.J.
STAMS, K.R. *see* GRIMM, S.W.
STEPHENSON, T. The medicines for children agenda in the UK: 716
STRICKER, B.H.CH. *see* MANTEL-TEEUWISSE, A.K.
STRICKER, B.H.CH. *see* ZIERE, G.
SUGAWARA, K. *see* SHIMIZU, M.
SUGAWARA, K. *see* UNO, T.
SUGIMOTO, M. *see* FURUTA, T.
SUISSA, S. *see* 'CHRIS' DELANEY, J.A.
SUZUKI, T. *see* MIURA, M.
SZABADI, E. Drugs for sleep disorders: mechanisms and therapeutic prospects: 761
SZABADI, E. *see* HOU, R.H.
SZARFMAN, A. *see* LEVINE, J.G.

TADA, H. *see* MIURA, M.
TAKIZAWA, D. *see* TAKIZAWA, E.
TAKIZAWA, E., TAKIZAWA, D., HIRAOKA, H., SAITO, S. & GOTO, F. Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans: 256
TALON, D. *see* MULLER, A.
TAL-SINGER, R. *see* SINGH, D.
TANAKA, T. *see* MURAKAMI, Y.
TASHIRO, M., MOCHIZUKI, H., SAKURADA, Y., ISHII, K., ODA, K., KIMURA, Y., SASAKI, T., ISHIWATA, K. & YANAI, K. Brain histamine H_1 receptor occupancy of orally administered antihistamines measured by positron emission tomography with ^{11}C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen: 16
TATEISHI, T. *see* MIURA, M.
TATEISHI, T. *see* SHIMIZU, M.
TATEISHI, T. *see* UNO, T.
TATEISHI, T. *see* YASUI-FURUKORI, N.
TATZBER, F. *see* RESCH, U.
TERHAAG, B. *see* BERNSDORF, A.
THEIS, J.G.W. *see* SIDHU, J.
THEUNISSEN, E.L., VERMEEREN, A. & RAMAEKERS, J.G. Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance: 79
THOMSON, A.H. *see* STAATZ, C.E.
THUILLEZ, C. *see* JOANNIDES, R.
TIRONA, R.G. & BAILEY, D.G. Herbal product–drug interactions mediated by induction: 677
TITCHEN, T., CRANSWICK, N. & BEGGS, S. Authors' response: Adverse drug reactions to NSAIDs: 240
TODROS, T., VERDIGLIONE, P., OGGÈ, G., PALADINI, D., VERGANI, P. & CARDAROPOLI, S. Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection: 336
TOMLINSON, B. & CHOW, M.S.S. Stereoselective interaction of manidipine and grapefruit juice: a new twist on an old tale: 529
TONNING, J.M. *see* LEVINE, J.G.
TRIENEKENS, P.H. *see* MANTEL-TEEUWISSE, A.K.
TSCHURLOVITS, M. *see* BRUNNER, M.
TSUJIMOTO, M. *see* MURAKAMI, Y.
TUCKER, A.T. *see* CHIK, Z.

UCHAIPICHAT, V., WINNER, L.K., MACKENZIE, P.I., ELLIOT, D.J., WILLIAMS, J.A. & MINERS, J.O. Quantitative prediction of *in vivo* inhibitory interactions involving glucuronidated drugs from *in vitro* data: the effect of fluconazole on zidovudine glucuronidation: 427
UNNEBRINK, K. *see* HESSE, C.
UNO, T. *see* MIURA, M.
UNO, T. *see* SHIMIZU, M.
UNO, T. *see* YASUI-FURUKORI, N.
UNO, T., OHKUBO, T., MOTOMURA, S. & SUGAWARA, K. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects: 533
UNO, T., SHIMIZU, M., YASUI-FURUKORI, N., SUGAWARA, K. & TATEISHI, T. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status: 309

VAN DER CAMMEN, T.J.M. *see* ZIERE, G.
VAN DER ENDE, M. *see* BURGER, D.
VAN DER HEIDEN, I. *see* BURGER, D.
VAN DER KLAAUW, A.A. *see* PEREIRA, A.M.
VAN DOORN, J. *see* PEREIRA, A.M.
VAN GIERSBERGEN, P.L.M. *see* DINGEMANSE, J.
VAN SCHAIK, R. *see* BURGER, D.
VAN THIEL, S.W. *see* PEREIRA, A.M.
VAUTIER, S. *see* WYPLOSZ, B.
VERDIGLIONE, P. *see* TODROS, T.
VERGANI, P. *see* TODROS, T.
VERMEEREN, A. *see* THEUNISSEN, E.L.
VERSCHUREN, W.M.M. *see* MANTEL-TEEUWISSE, A.K.
VESSEY, R. *see* SINGH, D.
VIGO, J.-M. *see* CASTEL, J.-M
VILLA, R. *see* BRUNNER, M.
VOELKER, J.R. *see* YEO, K.P.
VOLLEBREGT, J.A., METZ, J.C.M., DE HAAN, M., RICHIR, M.C., HUGTENBURG, J.G. & DE VRIES, T.P.G.M. Curriculum development in pharmacotherapy: testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial: 345

WAITMAN, D.-A. *see* KAHAN, N.R.
WALLER, D.P. *see* SIMOES, J.A.
WALLER, P. *see* BARROW, P.
WALLER, P.C., EVANS, S.J.W. & BEARD, K. Drug safety and the media: 123

WALSH, L. Incidental events in spontaneous reports – a proposal for filtering 'noise': 118
WANG, B. *see* DONNELLY, R.
WARD, S. *see* SIMPSON, J.A.
WARREN, J. *see* RITTER, J.
WATKINS, W.A. *see* SIMPSON, J.A.
WEGNER, D. *see* BERNSDORF, A.
WESSELS, D. *see* SINGH, D.
WILLIAMS, J.A. *see* UCHAIPICHAT, V.
WINNER, L.K. *see* UCHAIPICHAT, V.
WINSTANLEY, P. *see* SIMPSON, J.A.
WINTER, H.R. *see* GRIMM, S.W.
WISE, L. *see* BARROW, P.
WISE, S.D. *see* YEO, K.P.
WRISHKO, R.E. *see* FORGUE, S.T.
WYPLOSZ, B., VAUTIER, S., LILLO-LE LOUËT, A. & CAPRON, L. Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone: 474

YAMADA, H., SESOKO, S., DAIMON, T. & NAKASHIMA, M. Application of a newly designed electronic monitoring device for press through packaging sheets in a clinical trial: 238
YANAI, K. *see* TASHIRO, M.
YASUI-FURUKORI, N. *see* MIURA, M.
YASUI-FURUKORI, N. *see* UNO, T.
YASUI-FURUKORI, N., UNO, T., KANEKO, S. & TATEISHI, T. Author's reply: Hydroxylation of lansoprazole in poor metabolizers of CYP2C19: 361
YEO, K.P., LOWE, S.L., LIM, M.T., VOELKER, J.R., BURKEY, J.L. & WISE, S.D. Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction: 200
YEO, K.R. *see* REHILL, N.
YEO, W.W. *see* REHILL, N.

ZANEVELD, L.J.D. *see* SIMOES, J.A.
ZHANG, M. *see* GARDINER, S.J.
ZIEGLER, S. *see* BRUNNER, M.
ZIERE, G., DIELEMAN, J.P., HOFMAN, A., POLS, H.A.P., VAN DER CAMMEN, T.J.M. & STRICKER, B.H.CH. Polypharmacy and falls in the middle age and elderly population: 218
ZONDAG, E. *see* HESSE, C.

SUBJECT INDEX

This index was compiled from the keywords

β-adrenoceptor blockers, 513
μ-opiate-agonist, 27
6β-hydroxycortisol, 200
ACE inhibitors, 502
ACIDFORM, 211
activated charcoal, 177
adult growth hormone deficiency, 451
adverse cardiovascular events, 464
adverse drug reaction, 233
adverse effects, 738
adverse events, 224
adverse oesophageal effects, 470
age, 605
aldosterone, 738
alendronate, 470
allometric scaling, 545
amikacin, 39
analgesics, 389
angiotensin receptor blockers, 502
antibacterials, 96
anticoagulants, 229
antiepileptic drugs, 246
antihistamine, 79
antimicrobial use, 585
antioxidant treatment, 5
antioxidants, 774
arousal, 752
artemisinin, 666
arteries, 767
artesunate, 690
aspirin, 730
autoantibodies, 262

bacterial vaginosis, 211
bioequivalence, 275
bisphosphonates, 521
bladder, 456
bone fractures, 521
breast milk, 155
British National Formulary for Children, 716
budesonide, 31

calcitriol, 470
carbamazepine, 58
cardiac, 727
cardiac failure, 727
cardiothoracic surgery, 164
cardiovascular risk, 494, 502, 601
case–control, 730
case–control studies, 229
catecholamines, 127
cefuroxime, 341
celecoxib, 101
cetirizine, 79
children, 545, 706
Chilean population, 778
China, 666, 702
chlorcycloguanil, 289
chlorproguanil, 289, 690
chronic medication, 352
ciclosporin A, 671
ciprofibrate, 694
ciprofloxacin, 138
citalopram, 177
clearance, 545
clinical pharmacology, 389, 787
clinical pharmacology and therapeutics, 345
codispensing, 470
cognitive skills, 345
combined oral contraceptive, 191
communication, 702, 787
community consumption, 96
comparison, 720
compliance, 352
computer decision support, 371
congenital long QT syndrome (LQTS), 464
congestive cardiac failure, 502, 513
coronary artery disease, 720
coumarins, 746
crystalloid resuscitation, 256
cyclosporin, 706
CYP2B6 polymorphism, 148
CYP2C19, 309, 315
CYP2C8, 70, 746
CYP2C8 polymorphism, 49
CYP2D6, 321
CYP2D6 polymorphism, 558
CYP3A4, 200, 533
Cypher, 720
cytochrome P450, 321, 379, 570
cytochrome P450 enzymes, 677

dapsone, 289, 690
defined daily dose, 585
depression, 155
determinants of antibiotic use, 96
detrusor overactivity, 456
development, 355
Diabetes mellitus, 702
diazepam, 752
diltiazem, 538
diphenhydramine, 752
DNA polymorphisms, 778
dosage, 671
driving, 79
drug discovery, 666
drug interaction, 58, 70, 538, 671, 741
drug interactions, 246, 427, 677
drug resistance, 690
drug safety, 123, 233
drug therapy, 716, 761
drug therapy/adverse effects, 371
drug utilization, 96
drug utilization analysis, 341

efavirenz, 148, 601
elderly, 218, 229
elderly patients, 494, 502, 513, 521
electrolytes, 87
emergency hormonal contraception, 605
enantiomer, 315, 533
endothelin, 405
endothelium, 767
enzyme induction, 200, 246, 246
epidemiology, 229, 730
epilepsy, 246
erectile dysfunction, 280
ethnic origin, 405
ethnicity, 148
exercise, 127
exponents, 545
extreme preterm infants, 39

falls, 218
fexofenadine, 538
first-generation antihistamine, 16
fluconazole, 427
fluoxetine, 155
fluvoxamine, 309
food, 682
food effect, 31

gastrointestinal transit, 31
Ge Hong, 666
gender, 148, 682
genetic polymorphisms, 301
genetic variants, 778
gentamicin, 164
geriatric medicine, 218
geriatrics, 558
glucoronidation, 326, 427
grapefruit juice, 49, 533, 682
guideline adherence, 592

haemodynamic, 127
HapMap, 783
HDL-cholesterol, 601
healthy subject, 398
Herbal formulations, 677
HES data, 233
histamine H_1-receptor (H_1R), 16
histamine H_1-receptor occupancy, 16
HIV, 379
HIV-infection, 5
HIV infection, 148, 601

© 2006 Blackwell Publishing Ltd

hospital, 585
hospital admission, 233
human, 101
human pain models, 389
hydroxymethylglutaryl-CoA reductase inhibitors, 592
hyperalgesia, 389
hypercholesterolaemia, 592
hyperlipidaemia, 694
hypokalaemia, 87
hyponatraemia, 87

I_{Ks} currents, 464
impulse oscillometry, 398
in vitro-in vivo correlation, 427
incidence, 470
indicators, 585
induction, 677
ineffectiveness, 352
inhibition, 326
interaction, 191
Internet, 787
ion channels, 301
isoniazid, 570
isoquine, 690
isovolaemic haemorrhage, 256
itraconazole, 538
ivabradine, 127

Japanese, 405

KCNQ1, 464
ketoconazole, 58
ketotifen, 16

lactation, 101
lamotrigine, 191, 420
Lapdap, 690
lasofoxifene, 741
light reflex, 752
long QT syndrome, 301
loperamide, 27
lung function, 398

Malaria, 666, 682, 690
managed care, 341
manidipine, 533
MAO inhibitors, 570
mass media, 123
mechanism-based inactivation, 570
media, 224
Medicines for Children, 716
medicines regulation, 371
mequitazine, 79
meta-analysis, 720
metabolic ratio, 321
metabolic syndrome, 694
metabolism, 70
metabolite effects, 138
methadone, 326
metronidazole, 211
microbicide, 211
milk, 101
modelling, 177
monitoring, 371
morphine, 326
motion sickness, 27
MRP2, 440
myocardial infarction, 513, 730

N-acetylcysteine, 5
nausea, 27
needle-free, 451
neural mechanisms, 761
neurokinin-1 receptor antagonist, 414
nitric oxide, 767
noncompetitive, 326
NONMEM, 558
non-nucleoside reverse transcriptase inhibitor, 148
Non-selective non-steroidal anti-inflammatory drugs, 738
nonselective COX inhibitors, 39
non-steroidal anti-inflammatory drugs, 730
nonsteroidal anti-inflammatory drugs, 389
norfluoxetine, 155

OATP1B1, 440, 706
olanzapine, 420
olopatadine, 16
orphan drugs, 355
osteoporosis, 521
oxidative stress, 262, 774
oxidatively modified low-density lipoprotein, 262

paediatrics, 716
paraoxonase, 694
paroxetine, 224, 558
patients' perspective, 352
pentoxifylline, 138
perhexiline, 321
personalized prescribing, 783
P-glycoprotein, 379, 440, 538
pharmacodynamics, 177, 191, 256, 289, 405, 741
pharmaco-epidemiology, 218
pharmacoepidemiology, 341
pharmacogenetics, 746, 778
pharmacogenomics, 783
pharmacokinetic model, 671
pharmacokinetics, 39, 58, 70, 101, 138, 148, 191, 275, 280, 379, 405, 414, 420, 538, 558, 682, 741
pharmaco-scintigraphy, 31
pharmacovigilance, 123, 233
pharmacy, 605
phosphodiesterase, 280
pioglitazone, 70
placebo-controlled crossover study design, 16
plasma concentrations, 601
Plasmodium falciparum, 289
polymorphism, 321
polypharmacy, 218
population pharmacokinetics, 164, 289
positron emission tomography (PET), 16
postpartum, 155
pravastatin, 706
pregnancy, 155
pregnancy-induced hypertension, 336
prevention and control, 371
primaquine, 682
primary care, 87
primary prevention, 494
prior authorization, 341
propofol, 256
propranolol, 127
protein kinase C β, 200
psychomotor performance, 79
pulmonary disease, 5
pupil, 752

qinghaosu, 666
QT interval, 177
QT prolongation, 464
quetiapine, 58

rabeprazole, 309, 315
radiocontrast-induced nephropathy, 5
randomized controlled trials, 494, 502, 513, 521
rare diseases, 355
recombinant human growth hormone, 451
regional differences, 96
repaglinide, 49
repeated-dose, 79
research, 702, 787
retinal blood flow, 138
review, 246
rifampicin, 138, 200, 70
risk drugs, 218
root mean square error, 545
rosuvastatin, 262
ruboxistaurin, 200

saquinavir, 379
secondary prevention, 494
second-generation antihistamine, 16
selective serotonin reuptake inhibitors, 224
sentinel effect, 341
serious motor vehicle crash, 229
sex, 379
sibutramine, 464
side-effects, 352
simvastatin, 440
skin conductance, 752
SLCO1B1, 706
Sleep disorders, 761
sleep-promoting system, 761
SLV317, 414
smoking, 730, 767
spiramycin, 336
St John's wort, 671, 677
statins, 494
Stem cells, 727
stereoselective drug disposition, 155
stereoselectivity, 326
stress hormones, 27
substance P, 414

tadalafil, 280
talinolol, 440
target concentration intervention, 39
targeted drug delivery, 31
Taxus, 720
TDS®, 275
testosterone, 275
tezosentan, 405
therapeutic drug monitoring, 321
therapeutic problem solving, 345
thiazide diuretics, 87
thromboembolism, 746
thrombolytic agents, 513
tilt, 127
time trends, 224
tolerability, 420
toxicology, 177
toxoplasmosis, 336
traditional Chinese medicine, 702
training, 702, 787
tramadol, 456
transdermal delivery, 275
treatment, 456
TSER, 778

UDP-glucuronosyltransferase, 427
undergraduate medical education, 345
urinary incontinence, 456

vaginal formulation, 211
vancomycin, 164
variability, 39
vascular damage, 774
vein, 414
vitamin D, 521
VKORC1, 746

wakefulness-promoting systems, 761
warfarin, 229, 741, 746
world wide web, 787

Yellow Card, 233

zidovudine, 427

Contents

Volume 61, Number 1, January 2006

Editors' view

1 Today's science, tomorrow's medicines: *J.K. Aronson, M.S. Lennard, J.M. Ritter, N.S. Baber, E.J. Begg & L.D. Lewis*

Review

5 N-acetylcysteine – passe-partout or much ado about nothing?: *M.-L. Aitio*

***In vivo* receptor imaging**

16 Brain histamine H_1 receptor occupancy of orally administered antihistamines measured by positron emission tomography with ^{11}C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen: *M. Tashiro, H. Mochizuki, Y. Sakurada, K. Ishii, K. Oda, Y. Kimura, T. Sasaki, K. Ishiwata & K. Yanai*

Pharmacodynamics

27 μ-Opiate receptor agonists – a new pharmacological approach to prevent motion sickness?: *B. Otto, R.L. Riepl, C. Otto, J. Klose, P. Enck & S. Klosterhalfen*

Pharmacokinetics

31 Gastrointestinal transit, release and plasma pharmacokinetics of a new oral budesonide formulation: *M. Brunner, S. Ziegler, A.F.D. Di Stefano, P. Dehghanyar, K. Kletter, M. Tschurlovits, R. Villa, R. Bozzella, G. Celasco, L. Moro, A. Rusca, R. Dudczak & M. Müller*

39 Limited predictability of amikacin clearance in extreme premature neonates at birth: *K. Allegaert, B.J. Anderson, V. Cossey & N.H.G. Holford*

Drug metabolism

49 The impact of *CYP2C8* polymorphism and grapefruit juice on the pharmacokinetics of repaglinide: *T.B. Bidstrup, P. Damkier, A.K. Olsen, M. Ekblom, A. Karlsson & K. Brøsen*

Drug interactions

58 Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics: *S.W. Grimm, N.M. Richtand, H.R. Winter, K.R. Stams & S.B. Reele*

70 Effect of rifampicin on the pharmacokinetics of pioglitazone: *T. Jaakkola, J.T. Backman, M. Neuvonen, J. Laitila & P.J. Neuvonen*

Therapeutics

79 Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance: *E.L. Theunissen, A. Vermeeren & J.G. Ramaekers*

87 Thiazide diuretic prescription and electrolyte abnormalities in primary care: *J.A. Clayton, S. Rodgers, J. Blakey, A. Avery & I.P. Hall*

Pharmacoepidemiology

96 Regional variations in community consumption of antibiotics in Hungary, 1996–2003: *M. Matuz, R. Benko, P. Doro, E. Hajdu, G. Nagy, E. Nagy, D.L. Monnet & G. Soos*

Short report

101 Quantification of infant exposure to celecoxib through breast milk: *S.J. Gardiner, M.P. Doogue, M. Zhang & E.J. Begg*

Letters to the editors

105 Reply: The evaluation of data mining methods for the simultaneous and systematic detection of safety signals in large databases: lessons to be learned: *J.G. Levine, J.M. Tonning & A. Szarfman*

114 Erratum

115 Response to letter by Levine *et al*: *M. Hauben & L. Reich*

118 Incidental events in spontaneous reports – a proposal for filtering 'noise': *L. Walsh*

Volume 61, Number 2, February 2006

Editors' view

121 Medicines and the media: *J.K. Aronson*

Review

123 Drug safety and the media: *P.C. Waller, S.J.W. Evans & K. Beard*

Pharmacodynamics

127 Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise: *R. Joannides, N. Moore, M. Iacob, P. Compagnon, G. Lerebours, J.-F. Menard & C. Thuillez*

138 A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans: *M. Magnusson, I.C. Bergstrand, S. Björkman, A. Heijl, B. Roth & P. Höglund*

Pharmacokinetics

148 Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and *CYP2B6* polymorphism: *D. Burger, I. van der Heiden, C. la Porte, M. van der Ende, P. Groeneveld, C. Richter, P. Koopmans, F. Kroon, H. Sprenger, J. Lindemans, P. Schenk & R. van Schaik*

155 Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding: *J. Kim, K.W. Riggs, S. Misri, N. Kent, T.F. Oberlander, R.E. Grunau, C. Fitzgerald & D.W. Rurak*

164 Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery: *C.E. Staatz, C. Byrne & A.H. Thomson*

Pharmacokinetics & pharmacodynamics

177 Pharmacokinetic–pharmacodynamic modelling of QT interval prolongation following citalopram overdoses: *L.E. Friberg, G.K. Isbister & S.B. Duffull*

Drug interactions

191 The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects: *J. Sidhu, S. Job, S. Singh & R. Philipson*

200 Pharmacokinetics of ruboxistaurin are significantly altered by rifampicin-mediated CYP3A4 induction: *K.P. Yeo, S.L. Lowe, M.T. Lim, J.R. Voelker, J.L. Burkey & S.D. Wise*

Therapeutics

211 A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis: *J.A. Simoes, L.G. Bahamondes, R.P.S. Camargo, V.M.N. Alves, L.J.D. Zaneveld, D.P. Waller, J. Schwartz, M.M. Callahan & C.K. Mauck*

Pharmacoepidemiology

218 Polypharmacy and falls in the middle age and elderly population: *G. Ziere, J.P. Dieleman, A. Hofman, H.A.P. Pols, T.J.M. van der Cammen & B.H.CH. Stricker*

Short reports

224 Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004: *R.M. Martin, M. May & D. Gunnell*

229 Warfarin use and the risk of motor vehicle crash in older drivers: *J.A. 'Chris' Delaney, L. Opatrny & S. Suissa*

233 Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions: *P. Barrow, P. Waller & L. Wise*

Letters to the editors

238 Application of a newly designed electronic monitoring device for press through packaging sheets in a clinical trial: *H. Yamada, S. Sesoko, T. Daimon & M. Nakashima*

240 Adverse drug reactions to NSAIDs: *D. Kanabar*

240 Authors' response: Adverse drug reactions to NSAIDs: *T. Titchen, N. Cranswick, S. Beggs*

Book review

242 Cannabinoids as Therapeutics: *R. Mechoulam*

Volume 61, Number 3, March 2006

Editors' view

243 Rare diseases and orphan drugs: *J.K. Aronson*

Review

246 Clinically relevant drug interactions with antiepileptic drugs: *E. Perucca*

Pharmacodynamics

256 Disposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans: *E. Takizawa, D. Takizawa, H. Hiraoka, S. Saito & F. Goto*

262 Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy: *U. Resch, F. Tatzber, A. Budinsky & H. Sinzinger*

Pharmacokinetics

275 Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males: *Z. Chik, A. Johnston, A.T. Tucker, S.L. Chew, L. Michaels & C.A.S. Alam*

280 Tadalafil pharmacokinetics in healthy subjects: *S.T. Forgue, B.E. Patterson, A.W. Bedding, C.D. Payne, D.L. Phillips, R.E. Wrishko & M.I. Mitchell*

Pharmacokinetics & pharmacodynamics

289 Population pharmacokinetic and pharmacodynamic modelling of the antimalarial chemotherapy chlorproguanil/dapsone: *J.A. Simpson D. Hughes, C. Manyando, K. Bojang, L. Aarons, P. Winstanley, G. Edwards, W.A. Watkins & S. Ward*

Pharmacogenetics

301 Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore: *S.H. Koo, W.F. Ho & E.J.D. Lee*

309 Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status: *T. Uno, M. Shimizu, N. Yasui-Furukori, K. Sugawara & T. Tateishi*

315 Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes: *M. Miura, H. Kagaya, H. Tada, T. Uno, N. Yasui-Furukori, T. Tateishi & T. Suzuki*

321 The influence of *CYP2D6* genotype on trough plasma perhexiline and *cis*-OH-perhexiline concentrations following a standard loading regimen in patients with myocardial ischaemia: *B.J. Davies, J.K. Coller, H.M. James, A.A. Somogyi, J.D. Horowitz & B.C. Sallustio*

Drug metabolism

326 Differential *in vitro* inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids: *G.A. Morrish, D.J.R. Foster & A.A. Somogyi*

Therapeutics

336 Low incidence of hypertensive disorders of pregnancy in women treated with spiramycin for toxoplasma infection: *T. Todros, P. Verdiglione, G. Oggè, D. Paladini, P. Vergani & S. Cardaropoli*

Prescribing

341 When gatekeepers meet the sentinel: the impact of a prior authorization requirement for cefuroxime on the prescribing behaviour of community-based physicians: *N.R. Kahan, D.P. Chinitz, D.-A. Waitman & E. Kahan*

Education

345 Curriculum development in pharmacotherapy: testing the ability of preclinical medical students to learn therapeutic problem solving in a randomized controlled trial: *J.A. Vollebregt, J.C.M. Metz, M. de Haan, M.C. Richir, J.G. Hugtenburg & T.P.G.M. de Vries*

Short reports

352 Initial phase of chronic medication use; patients' reasons for discontinuation: *J.G. Hugtenburg, A.T.G. Blom & S.U. Kisoensingh*

355 Orphan drug development is progressing too slowly: *R. Joppi, V. Bertele & S. Garattini*

Letters to the editors

361 Hydroxylation of lansoprazole in poor metabolizers of CYP2C19: *T. Furuta, N. Shirai, M. Sugimoto, A. Nakamura & A. Hishida*

361 Author's reply: Hydroxylation of lansoprazole in poor metabolizers of CYP2C19: *N. Yasui-Furukori, T. Uno, S. Kaneko & T. Tateishi*

363 ASCOT – old or new drugs for blood pressure?: *J. Ritter & J. Warren*

Volume 61, Number 4, April 2006

Editors' view

365 Monitoring for harms of therapy: *J.K. Aronson*

Commentary

367 The phase 0 microdosing concept: *R.C. Garner & G. Lappin*

Review

371 Monitoring for adverse drug reactions: *J.J. Coleman, R.E. Ferner & S.J.W. Evans*

Pharmacokinetics

379 Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort: *S.M. Robertson, E. Formentini, R.M. Alfaro, V. Natarajan, J. Falloon & S.R. Penzak*

Pharmacodynamics

389 Hyperalgesia induced by cutaneous freeze injury for testing analgesics in healthy volunteers: *C. Chassaing, J. Schmidt, A. Eschalier, J.M. Cardot & C. Dubray*

398 Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects: *D. Singh, R. Tal-Singer, I. Faiferman, S. Lasenby, A. Henderson, D. Wessels, A. Goosen, N. Dallow, R. Vessey & M. Goldman*

Pharmacokinetics & pharmacodynamics

405 Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between Caucasian and Japanese subjects: *J. Dingemanse, K.A. Gunawardena & P.L.M. van Giersbergen*

414 Kinetics and dynamics of the peripheral neurokinin-1 receptor antagonist SLV317 in healthy individuals: *C. Hesse, S.P. Luntz, H. Siedler, K. Unnebrink, G. Mikus, M. de Bruijn, E. Zondag, M. de Vries, M. Seibert-Grafe & W.E. Haefeli*

420 Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects: *J. Sidhu, S. Job, J. Bullman, E. Francis, R. Abbott, J. Ascher & J.G.W. Theis*

Drug interactions

427 Quantitative prediction of *in vivo* inhibitory interactions involving glucuronidated drugs from *in vitro* data: the effect of fluconazole on zidovudine glucuronidation: *V. Uchaipichat, L.K. Winner, P.I. Mackenzie, D.J. Elliot, J.A. Williams & J.O. Miners*

440 Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms: *A. Bernsdorf, T. Giessmann, C. Modess, D. Wegner, S. Igelbrink, U. Hecker, S. Haenisch, I. Cascorbi, B. Terhaag & W. Siegmund*

Therapeutics

451 Efficacy of needle-free administration of recombinant human growth hormone in adults with growth hormone deficiency: *A.M. Pereira, A.A. van der Klaauw, H.P.F. Koppeschaar, J.W.A. Smit, S.W. van Thiel, J. van Doorn, N.R. Biermasz, F. Roelfsema & J.A. Romijn*

456 Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study: *M.R. Safarinejad & S.Y. Hosseini*

Adverse drug reactions

464 QT interval prolongation associated with sibutramine treatment: *M. Harrison-Woolrych, D.W.J. Clark, G.R. Hill, M.I. Rees & J.R. Skinner*

Short report

470 A study of codispensing with sodium alendronate in Australia: *I.W. Boyd, J. McEwen & L.J. Calcino*

Letter to the editors

474 Tolerance of diclofenac after hypersensitivity to celecoxib and to nabumetone: *B. Wyplosz, S. Vautier, A. Lillo-Le Louët & L. Capron*

475 Proceedings of the Dutch Society of Clinical Pharmacology and Biopharmacy meeting of October 4th 2005

Volume 61, Number 5, May 2006

Editors' view

487 A prescription for better prescribing: *J.K. Aronson*

Editors' report

492 Editors' Report 2005: *J.K. Aronson, M.S. Lennard, J.M. Ritter, N.S. Baber, E.J. Begg, L.D. Lewis*

Reviews

494 The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention: *A.A. Mangoni & S.H.D. Jackson*

502 The implications of a growing evidence base for drug use in elderly patients. Part 2. ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients: *A.A. Mangoni & S.H.D. Jackson*

513 The implications of a growing evidence base for drug use in elderly patients. Part 3. β-adrenoceptor blockers in heart failure and thrombolytics in acute myocardial infarction: *A.A. Mangoni & S.H.D. Jackson*

521 The implications of a growing evidence base for drug use in elderly patients. Part 4. Vitamin D and bisphosphonates for fractures and osteoporosis: *J.K. Dhesi, T.J. Allain, A.A. Mangoni & S.H.D. Jackson*

Editorial commentary

529 Stereoselective interaction of manidipine and grapefruit juice: a new twist on an old tale: *B. Tomlinson & M.S.S. Chow*

Drug disposition

533 Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects: *T. Uno, T. Ohkubo, S. Motomura & K. Sugawara*

538 Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein: *M. Shimizu, T. Uno, K. Sugawara & T. Tateishi*

545 Prediction of drug clearance in children from adults: a comparison of several allometric methods: *I. Mahmood*

Pharmacokinetics

558 Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling: *Y. Feng, B.G. Pollock, R.E. Ferrell, M.A. Kimak, C.F. Reynolds III & R.R. Bies*

Drug metabolism

570 An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid: *T.M. Polasek, D.J. Elliot, A.A. Somogyi, E.M.J. Gillam, B.C. Lewis & J.O. Miners*

Therapeutics

585 Discrepancies between prescribed daily doses and WHO defined daily doses of antibacterials at a university hospital: *A. Muller, D.L. Monnet, D. Talon, T. Hénon & X. Bertrand*

592 Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992–1999): *A.K. Mantel-Teeuwisse, O.H. Klungel, A. Hofman, W.M.M. Verschuren, P.H. Trienekens, A.J. Porsius, B.H.CH. Stricker & A. de Boer*

Short reports

601 Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients: *S.A. Pereira, T. Branco, R.M. Côrte-Real, I. Germano, F. Lampreia, U. Caixas & E.C. Monteiro*

605 Access to emergency hormonal contraception from community pharmacies and family planning clinics: *G. Lewington & K. Marshall*

Letter to the editors

609 Bilateral plantar tendinitis during levofloxacin therapy: *J. Beyer & S. Schellong*

Book reviews

610 Platelet function: assessment, diagnosis and treatment: *Edited by M. Quinn & D. Fitzgerald; reviewed by A. Ferro*

611 Drug Interactions in Infectious Diseases, 2nd edn: *Edited by S.C. Piscitelli & K.A. Rodvald; reviewed by D. Back*

612 Proceedings of the British Pharmacological Society Clinical Pharmacology Section 19–22 December 2005

Volume 61, Number 6, June 2006

647 Clinical Pharmacology: Past, Present, and Future: *J.K. Aronson*

650 Clinical pharmacology – the first 75 years and a view of the future: *C.T. Dollery*

666 Reflections on the 'discovery' of the antimalarial *qinghao*: *E. Hsu*

671 Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A: *Y. Murakami, T. Tanaka, H. Murakami, M. Tsujimoto, H. Ohtani & Y. Sawada*

677 Herbal product–drug interactions mediated by induction: *R.G. Tirona & D.G. Bailey*

682 Does gender, food or grapefruit juice alter the pharmacokinetics of primaquine in healthy subjects?: *B.T. Cuong, V.Q. Binh, B.D.D.N. Duy, C.M. Lovell, K.H. Rieckmann & M.D. Edstein*

690 Resisting resistance: dealing with the irrepressible problem of malaria: *G. Edwards & G.A. Biagini*

694 Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome: *G. Paragh, I. Seres, M. Harangi, A. Erdei, M. Audikovszky, L. Debreczeni, A. Kovácsay, L. Illyés & G. Pados*

702 Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments: *R. Donnelly, B. Wang & X. Qu*

706 Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the *SLCO1B1* and *ABCB1* genes: *M. Hedman, M. Antikainen, C. Holmberg, M. Neuvonen, M. Eichelbaum, K.T. Kivistö, P.J. Neuvonen & M. Niemi*

716 The medicines for children agenda in the UK: *T. Stephenson*

720 A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease: *S. Sidhu, N. Shafiq, S. Malhotra, P. Pandhi & A. Grover*

727 Cardiac stem cell therapy: present and future: *M. Saha & A. Ferro*

730 Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs: *C.J. Hawkey, G.M. Hawkey, S. Everitt, M.M. Skelly, W.A. Stack & D. Gray*

738 Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime?: *K.M. Knights, A.A. Mangoni & J.O. Miners*

741 Effects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin: *D. Ouellet, C. Bramson, S. Carvajal-Gonzalez, D. Roman, E. Randinitis, A. Remmers & M.J. Gardner*

746 The future prospects of pharmacogenetics in oral anticoagulation therapy: *F. Kamali & M. Pirmohamed*

752 Relationship between sedation and pupillary function: comparison of diazepam and diphenhydramine: *R.H. Hou, J. Scaife, C. Freeman, R.W. Langley, E. Szabadi & C.M. Bradshaw*

761 Drugs for sleep disorders: mechanisms and therapeutic prospects: *E. Szabadi*

767 The effect of chronic tobacco smoking on arterial stiffness: *N. Rehill, C.R. Beck, K.R. Yeo & W.W. Yeo*

774 Oxidative stress, antioxidants, and vascular damage: *P. Minuz, C. Fava & L. Cominacini*

778 Genetic variants in the enhancer region of the thymidylate synthase gene in the Chilean population: *M. Acuña, L. Eaton, L. Cifuentes & D. Massardo*

783 HapMap, pharmacogenomics, and the goal of personalized prescribing: *K.M. O'Shaughnessy*

787 The internet as a tool in clinical pharmacology: *J.-M. Castel, A. Figueras & J.-M. Vigo*

791 Indexes for Volume 61